CoChat
Sign Up
Cited by 184

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

Sieper, Joachim, Porter-Brown, Benjamin, Thompson, Liz, Harari, Olivier, Dougados, Maxime·2014·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2013-203559PMC PMC3888605
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2013-203559

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition for BUILDER-1 parts 1 and 2 at 12 and 24 weeks. TCZ, tocilizumab.
Figure 1 Patient disposition for BUILDER-1 parts 1 and 2 at 12 and 24 weeks. TCZ, tocilizumab.CC BY-NC · PubMed Central
Figure 2 (A) ASAS20 and (B) ASAS40 response rates at week 12 in BUILDER-1 part 1 (intention-to-treat population; significance was determined using a logistic regression adjusted for region) for the entire group and (C) by CRP levels at baseline. ASAS20, 20% improvement in the Assessments in Ankylosing Spondylitis Response Criteria; CRP, C reactive protein; TCZ, tocilizumab; ULN, upper limit of normal.
Figure 2 (A) ASAS20 and (B) ASAS40 response rates at week 12 in BUILDER-1 part 1 (intention-to-treat population; significance was determined using a logistic regression adjusted for region) for the entire group and (C) by CRP levels at baseline. ASAS20, 20% improvement in the Assessments in Ankylosing Spondylitis Response Criteria; CRP, C reactive protein; TCZ, tocilizumab; ULN, upper limit of normal.CC BY-NC · PubMed Central
Figure 3 BASDAI total score over time in BUILDER-1 part 1 (intention-to-treat population). Error bars represent 95% CIs. Missing components were imputed using last observation carried forward. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; TCZ, tocilizumab.
Figure 3 BASDAI total score over time in BUILDER-1 part 1 (intention-to-treat population). Error bars represent 95% CIs. Missing components were imputed using last observation carried forward. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; TCZ, tocilizumab.CC BY-NC · PubMed Central
Figure 4 Median change in CRP levels from baseline to week 12 in BUILDER-1 part 1 (intention-to-treat population). Error bars represent IQRs. CRP, C reactive protein; TCZ, tocilizumab.
Figure 4 Median change in CRP levels from baseline to week 12 in BUILDER-1 part 1 (intention-to-treat population). Error bars represent IQRs. CRP, C reactive protein; TCZ, tocilizumab.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 41

  1. Tam, 2010, Pathogenesis of ankylosing spondylitis, Nat Rev Rheumatol, 6, 399, 10.1038/nrrheum.2010.79 · DOI
  2. Rosenbaum, 2012, Management of comorbidities in ankylosing spondylitis, Am J Med Sci, 343, 364, 10.1097/MAJ.0b013e3182514059 · DOI
  3. Akkoc, 2005, Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al, Arthritis Rheum, 52, 4048, 10.1002/art.21492 · DOI
  4. Braun, 2011, 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Ann Rheum Dis, 70, 896, 10.1136/ard.2011.151027 · DOI
  5. Zochling, 2006, Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis: a population-based survey, Clin Rheumatol, 25, 794, 10.1007/s10067-005-0132-y · DOI
  6. Roychowdhury, 2002, Is methotrexate effective in ankylosing spondylitis?, Rheumatology, 41, 1330, 10.1093/rheumatology/41.11.1330 · DOI
  7. Altan, 2001, Clinical investigation of methotrexate in the treatment of ankylosing spondylitis, Scand J Rheumatol, 30, 255, 10.1080/030097401753180318 · DOI
  8. Braun, 2005, Therapy of ankylosing spondylitis: a review. Part I: conventional medical treatment and surgical therapy, Scand J Rheumatol, 34, 97, 10.1080/03009740510018679 · DOI
  9. Inman, 2008, Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial, Arthritis Rheum, 58, 3402, 10.1002/art.23969 · DOI
  10. Braun, 2002, Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, Lancet, 359, 1187, 10.1016/S0140-6736(02)08215-6 · DOI
  11. Brandt, 2003, Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum, 48, 1667, 10.1002/art.11017 · DOI
  12. Van Der Heijde, 2009, Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial, Ann Rheum Dis, 68, 922, 10.1136/ard.2007.087270 · DOI
  13. Van Der Heijde, 2006, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 54, 2136, 10.1002/art.21913 · DOI
  14. Davis, 2003, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial, Arthritis Rheum, 48, 3230, 10.1002/art.11325 · DOI
  15. Van Der Heijde, 2005, Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum, 52, 582, 10.1002/art.20852 · DOI
  16. Rudwaleit, 2009, Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis, J Rheumatol, 36, 801, 10.3899/jrheum.081048 · DOI
  17. Van Der Heijde, 2008, Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis, Arthritis Rheum, 58, 3063, 10.1002/art.23901 · DOI
  18. Gratacos, 1994, Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity, Br J Rheumatol, 33, 927, 10.1093/rheumatology/33.10.927 · DOI
  19. Gratacos, 1999, Significant loss of bone mass in patients with early, active ankylosing spondylitis: a follow-up study, Arthritis Rheum, 42, 2319, 10.1002/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO;2-G · DOI
  20. Falkenbach, 1998, In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility, Rheumatol Int, 18, 103, 10.1007/s002960050066 · DOI
  21. Bal, 2007, Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis, Clin Rheumatol, 26, 211, 10.1007/s10067-006-0283-5 · DOI
  22. Tutuncu, 1994, Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis, Ann Rheum Dis, 53, 425, 10.1136/ard.53.6.425-b · DOI
  23. Visvanathan, 2008, Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab, Ann Rheum Dis, 67, 511, 10.1136/ard.2007.071605 · DOI
  24. Visvanathan, 2009, Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis, Ann Rheum Dis, 68, 175, 10.1136/ard.2007.084426 · DOI
  25. Mihara, 2005, Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family, Int Immunopharmacol, 5, 1731, 10.1016/j.intimp.2005.05.010 · DOI
  26. Emery, 2008, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial, Ann Rheum Dis, 67, 1516, 10.1136/ard.2008.092932 · DOI · Paper page
  27. Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis, 69, 88, 10.1136/ard.2008.105197 · DOI · Paper page
  28. Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 · DOI
  29. Kremer, 2011, Arthritis Rheum, 63, 609, 10.1002/art.30158 · DOI
  30. van der Linden, 1984, Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria, Arthritis Rheum, 27, 361, 10.1002/art.1780270401 · DOI
  31. Brulhart, 2010, Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists, Joint Bone Spine, 77, 625, 10.1016/j.jbspin.2010.08.004 · DOI
  32. Henes, 2010, Mixed response to tocilizumab for ankylosing spondylitis, Ann Rheum Dis, 69, 2217, 10.1136/ard.2009.126706 · DOI
  33. Shima, 2011, Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis, Modern Rheumatol, 21, 436, 10.3109/s10165-011-0416-9 · DOI
  34. Cohen, 2011, Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab, J Rheumatol, 38, 1527, 10.3899/jrheum.110265 · DOI
  35. Dudler, 2011, Tocilizumab in axial spondylarthropathies: about 18 cases [abstract], Ann Rheum Dis, 70, 128
  36. Del Castillo Piñol, 2011, Tocilizumab for treatment of refractory spondyloarthritis: report of 5 patients [abstract], Ann Rheum Dis, 70, 343
  37. Haibel, 2005, Open label trial of anakinra in active ankylosing spondylitis over 24 weeks, Ann Rheum Dis, 64, 296, 10.1136/ard.2004.023176 · DOI
  38. Song, 2011, Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study, Ann Rheum Dis, 70, 1108, 10.1136/ard.2010.145946 · DOI
  39. Park, 2007, Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis, Scand J Rheumatol, 36, 101, 10.1080/03009740600991760 · DOI
  40. Sieper, 2012, Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN) [abstract], Ann Rheum Dis, 71, 111, 10.1136/annrheumdis-2012-eular.1852 · DOI
  41. Schiff, 2011, Integrated safety in tocilizumab clinical trials, Arthritis Res Ther, 13, 1, 10.1186/ar3455 · DOI

Cited by

Sorted by citations

See all 184

Metadata

Authors
Sieper, J., Porter-Brown, B., Thompson, L., Harari, O., & Dougados, M.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2014-01
Volume
73
Issue
1
Pages
95-100
ISSN
0003-4967
DOI
10.1136/annrheumdis-2013-203559
PMC
PMC3888605
Cited by
184
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. https://app.cochat.ai/papers/10.1136/annrheumdis-2013-203559
The paper
Sieper, J., Porter-Brown, B., Thompson, L., Harari, O., & Dougados, M. (2014). Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-203559